Preclinical
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
This is after Larimar reported deaths in the highest dose levels of a nonhuman primate toxicology study.
Engine is ready to drive its lead program into clinical trials by 2023 while Giiant’s preclinical program will target moderate-to-severe ulcerative colitis.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 25, 2021.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
The Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks the life cycle of the mosquito-borne parasite that causes malaria.
Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
NGM Bio’s aldafermin failed to hit its primary endpoint in its Phase IIB trial because of that, the company decides to shift resources to other programs.
If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.
PRESS RELEASES